Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation

Chao, Julie; Guo, Youming; Chao, Lee

doi:https://doi.org/10.1155/2018/4138560

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Conclusion Conflicts of Interest Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2018 | Article ID 4138560 | https://doi.org/10.1155/2018/4138560

Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation

Julie Chao,¹Youming Guo,¹and Lee Chao¹

Academic Editor: Roberto Carnevale

Received28 Jun 2018

Accepted04 Oct 2018

Published02 Dec 2018

Abstract

Kallistatin was identified in human plasma as a tissue kallikrein-binding protein and a serine proteinase inhibitor. Kallistatin exerts pleiotropic effects on angiogenesis, oxidative stress, inflammation, apoptosis, fibrosis, and tumor growth. Kallistatin levels are markedly reduced in patients with coronary artery disease, sepsis, diabetic retinopathy, inflammatory bowel disease, pneumonia, and cancer. Moreover, plasma kallistatin levels are positively associated with leukocyte telomere length in young African Americans, indicating the involvement of kallistatin in aging. In addition, kallistatin treatment promotes vascular repair by increasing the migration and function of endothelial progenitor cells (EPCs). Kallistatin via its heparin-binding site antagonizes TNF-α-induced senescence and superoxide formation, while kallistatin’s active site is essential for inhibiting miR-34a synthesis, thus elevating sirtuin 1 (SIRT1)/eNOS synthesis in EPCs. Kallistatin inhibits oxidative stress-induced cellular senescence by upregulating Let-7g synthesis, leading to modulate Let-7g-mediated miR-34a-SIRT1-eNOS signaling pathway in human endothelial cells. Exogenous kallistatin administration attenuates vascular injury and senescence in association with increased SIRT1 and eNOS levels and reduced miR-34a synthesis and NADPH oxidase activity, as well as TNF-α and ICAM-1 expression in the aortas of streptozotocin- (STZ-) induced diabetic mice. Conversely, endothelial-specific depletion of kallistatin aggravates vascular senescence, oxidative stress, and inflammation, with further reduction of Let-7g, SIRT1, and eNOS and elevation of miR-34a in mouse lung endothelial cells. Furthermore, systemic depletion of kallistatin exacerbates aortic injury, senescence, NADPH oxidase activity, and inflammatory gene expression in STZ-induced diabetic mice. These findings indicate that endogenous kallistatin displays a novel role in protection against vascular injury and senescence by inhibiting oxidative stress and inflammation.

1. Introduction

Aging is a major risk factor for the development of many diseases, including cardiovascular disease, stroke, and cancer [1–3]. Endothelial aging is associated with increased oxidative stress and inflammation and decreased endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) production [4, 5]. Excessive oxidative stress and chronic inflammation are common causes of endothelial dysfunction in vascular disease and aging [4]. Oxidative stress impairs the mobility and function of endothelial progenitor cells (EPCs) and enhances cellular senescence [6]. EPCs play an integral role in vascular repair by the replenishment of damaged or senescent endothelial cells [7]. Circulating EPC number and function are markedly reduced in the aging population [8–11]. Kallistatin in human plasma has been identified as a tissue kallikrein inhibitor and a unique serine proteinase inhibitor [12–16]. Kallistatin exerts multifactorial activities, including vasodilation and inhibition of oxidative stress, inflammation, fibrosis, and apoptosis, primarily by increasing eNOS levels and NO formation [17–22]. Moreover, kallistatin administration increases circulating EPC number and reduces aortic oxidative stress, whereas kallistatin depletion augments endothelial cell loss, diminishes circulating EPC levels, and exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling in hypertensive rats [23, 24]. Kallistatin protein treatment enhances the migration and function of cultured human EPCs [23]. Furthermore, plasma kallistatin levels are positively associated with leukocyte telomere length in young African Americans [25]. Telomere length is critically related to vascular cell senescence, and NO prevents telomere shortening by stimulating telomerase activity [26, 27]. Therefore, kallistatin via NO formation may protect against vascular injury, senescence, and aging through its antioxidant and anti-inflammatory actions.

2. Reduced Kallistatin Levels in Vascular Disease and Metabolic Disorders

Kallistatin is mainly synthesized in the liver and distributed in blood vessels and organs relevant to cardiovascular function [14, 28–30]. Human kallistatin gene transcripts and protein can be detected in the plasma, liver, heart, lung, kidney, prostate gland, and aorta [14, 28, 29]. Kallistatin is localized in endothelial and smooth muscle cells of large, medium, and small blood vessels [30]. Kallistatin levels are reduced in a variety of human diseases, such as coronary artery disease, sepsis, severe pneumonia, and active pulmonary tuberculosis, as well as colon, prostate, and liver cancer [29, 31–35]. Moreover, reduced plasma kallistatin levels are associated with elevated obesity and cardiometabolic risk in apparently healthy African Americans [36]. Likewise, kallistatin levels are lower in vitreous fluids from patients with diabetic retinopathy and in the retinas of streptozotocin- (STZ-) induced diabetic rats [37, 38]. However, elevated serum kallistatin has been observed in patients with diabetic vascular complications [39]. Moreover, plasma kallistatin levels are markedly reduced in animal models of hypertension, STZ-induced diabetes mellitus, lipopolysaccharide- (LPS-) induced endotoxemia, renal injury, and hepatocellular carcinoma [15, 18, 29, 40–42]. Circulating kallistatin levels are negatively associated with elevated thiobarbituric acid reactive substance (TBARS, an indicator of oxidative stress) in diabetic rats [43]. In addition, kallistatin levels are reduced in animal models and humans with inflammatory disorders [29, 33, 44]. These combined findings indicate that kallistatin levels are reduced under excess oxidative stress and inflammation, implicating the involvement of kallistatin in vascular damage and metabolic disorders.

3. Kallistatin as an Effective Antioxidant and Anti-Inflammatory Agent

Oxidative stress is the main cause of endothelial injury and vascular disease states, and inflammation is known to increase with aging [45, 46]. Kallistatin administration attenuates hypertension and organ damage in conjunction with increased eNOS and NO levels and reduced oxidative stress and inflammation in animal models [18, 19, 22, 23]. Kallistatin administration markedly reduces inflammatory responses in animal models of arthritis, hypertension, myocardial ischemia, and septic shock [17, 19, 21, 22, 47, 48]. Moreover, kallistatin overexpression protects against diabetic retinopathy in db/db mice by multiple mechanisms, including antioxidant, anti-inflammatory, antifibrotic, and blood pressure-lowering effects [49]. NO has antioxidant properties by inhibiting NADPH oxidase activity [50]. Kallistatin, via NO formation, reduces H₂O₂- or angiotensin II-induced NADPH oxidase activity and reactive oxygen species (ROS) formation in cultured endothelial cells, renal tubular cells, and cardiomyocytes [18, 22, 47]. Kallistatin inhibits vascular inflammation and apoptosis by stimulating eNOS synthesis and activation and NO formation [22, 51], as well as by preventing TNF-α- and high-mobility group box protein 1- (HMGB1-) mediated inflammatory gene expression [17, 21]. Thus, kallistatin appears to be a unique antioxidant and anti-inflammatory agent.

4. Kallistatin Reduces Senescence in EPCs and Endothelial Cells

EPCs are a subset of mononuclear cells derived from the bone marrow that have the ability to differentiate into mature endothelial cells [52]. Reduced EPC number is associated with defective proliferation and mobility as well as accelerated apoptosis and senescence [53]. Kallistatin depletion by neutralizing antibody injection augments glomerular endothelial cell loss and diminishes circulating EPC numbers [23, 24]. Excess oxidative stress or inflammation impairs the mobility and function of EPCs and increases cellular senescence [54, 55]. Indeed, recombinant human kallistatin treatment significantly inhibits TNF-α-induced EPC senescence by blocking oxidative stress and reducing the senescent markers plasminogen activator inhibitor (PAI)-1, microRNA- (miR-) 21, and p16^INK4a, while increasing telomerase activity [56]. The miR-34a-sirtuin 1 (SIRT1) axis is a key pathway in the aging process [57]. Kallistatin via its active site inhibits prosenescent miR-34a expression and antagonizes miR-34a-mediated inhibition of the antioxidant enzymes SIRT1 and eNOS in EPCs [56]. As a deacetylase, SIRT1 stimulates antioxidant enzymes including eNOS, catalase, and superoxide dismutase (SOD), and eNOS through NO production stimulates SIRT1 enzymatic activity and inhibits NADPH oxidase activity [58, 59], leading to the attenuation of oxidative stress. Similarly, kallistatin exerts salutary effects in the setting of H₂O₂-induced endothelial senescence, oxidative stress, and inflammation, as indicated by reduced p16^INK4a, PAI-1, and miR-34a synthesis, NADPH oxidase activity/expression, vascular cell adhesion molecule- (VCAM-) 1 and intercellular adhesion molecule- (ICAM-) 1 expression, and increased telomerase activity in endothelial cells [60]. Moreover, kallistatin via upregulating the endoprotective miRNA Let-7g coordinates Let-7g-modulated miR-34a-SIRT1-eNOS pathway and achieves antisenescent, antioxidant, and anti-inflammatory actions in endothelial cells [60]. Activation of SIRT1-eNOS signaling results in increased catalase and NO levels, thus suppressing oxidative vascular damage [60]. These combined studies reveal the mechanisms of kallistatin in protection against vascular injury by reducing cellular senescence in EPCs and endothelial cells.

5. Kallistatin Treatment Attenuates Vascular Injury and Senescence in Animal Models

As age advances, the alteration of vascular structure and function is intensified, such as endothelial senescence/rarefaction and increased oxidative stress and inflammation [61]. High blood glucose-induced vascular complications are manifested in diabetes [62]. The STZ-induced diabetic mouse is a popular model for studying vascular injury and aging [63, 64]. Kallistatin protein treatment inhibits aortic senescence and superoxide formation in association with reduced miR-34a synthesis and increased SIRT1 and eNOS expression in STZ-induced diabetic mice [56]. Moreover, kallistatin administration significantly inhibits inflammatory gene expression, such as TNF-α and ICAM-1, in the aorta of STZ-induced diabetic mice (Figure 1), indicating the beneficial effect of kallistatin in diabetes-associated vascular senescence, oxidative stress, and inflammation. In addition to diabetes, kallistatin gene delivery suppresses aortic superoxide formation and glomerular capillary loss in salt-induced hypertensive rats [22]. Likewise, kallistatin treatment attenuates cardiac dysfunction, apoptosis, and inflammation in conjunction with decreased oxidative stress and increased eNOS and NO levels in animal models of hypertension and myocardial infarction and ischemia-reperfusion injury [18, 19, 22, 47, 65]. Furthermore, kallistatin gene delivery inhibits vascular leakage in mice provoked by C5a and prevents arthritis-induced inflammation in rats [21]. Importantly, kallistatin is capable of improving oxidative stress-induced survival/aging at the organismal level in Caenorhabditis elegans by regulating the miR-34a-SIRT1 pathway [56]. Thus, as a potent antioxidant and anti-inflammatory agent, kallistatin could have a significant impact on vascular injury and senescence.

(a)

(b)

6. Endothelial-Specific Depletion of Kallistatin Exacerbates Cellular Senescence, Oxidative Stress, and Inflammation in Mouse Endothelial Cells

Endothelial-specific kallistatin knockout (KS^endo−/−) mice were generated by Cre-loxp recombination for exploring the role of endogenous kallistatin in diabetes-associated endothelial senescence, oxidative stress, and inflammation [60]. Mouse lung endothelial cells were isolated from 8-week-old KS^endo−/− and wild-type (WT) mice with CD31 immunoselection and cultured as described [66]. Kallistatin deficiency in mouse lung endothelial cells displayed aggravated senescence, oxidative stress, and inflammation, as evidenced by increases in senescence-associated (SA) β-gal activity, PAI-1/p16^INK4a synthesis, superoxide formation, and expression of the inflammatory genes ICAM-1, VCAM-1, and interleukin- (IL-) 6 [60]. Kallistatin deficiency in endothelial cells exacerbated oxidative stress-induced senescence, superoxide formation, NADPH oxidase activity, and inflammatory gene expression in endothelial cells, indicating a protective role of endogenous kallistatin in maintaining endothelial viability and function. Moreover, endothelial-specific depletion of kallistatin elevated senescence inducer miR-34a but reduced Let-7g and antioxidant genes, including SIRT1, eNOS, and catalase [60]. These findings support the notion that endogenous kallistatin acts as a protective molecule in endothelial senescence by inhibiting oxidative stress and inflammation.

7. Systemic Depletion of Kallistatin Aggregates Vascular Injury, Senescence, Oxidative Stress, and Inflammation in Diabetic Mice

Kallistatin depletion by neutralizing antibody injection aggravates aortic oxidative stress, capillary loss, and cardiovascular and renal remodeling, accompanied by elevated oxidative stress and inflammation in hypertensive rats [23, 24]. To further investigate the role of endogenous kallistatin in vascular injury and senescence, we generated systemic deficiency of kallistatin (KS^−/−) mice by Cre-loxp recombination technology [60]. Briefly, female homozygous floxed KS^fl/fl mice were crossed with male CAGCre⁺ mice for two generations to obtain CAGCre⁺KS^fl/fl mice. Tamoxifen was injected in these mice to induce Cre recombinase activity. The genotyping result showed that only KS^−/− mice were positive for deletion allele expression and negative for loxp and WT allele expression (Figure 2(a)). Kallistatin depletion was further identified by reduced mouse kallistatin protein levels in western blot analysis in the kidney of KS^−/− mice, compared with WT mice (Figure 2(b)). In contrast with kallistatin’s efficacy in aortic senescence and oxidative stress in STZ-induced diabetic mice [56], systemic depletion of kallistatin worsened vascular damage and senescence, characterized by aggravated aortic thickening, structural disarrangement, elevated SA-β-gal activity, and PAI-1 and p16^INK4a mRNA levels in the aorta of diabetic mice (Figures 2(c)–2(e)). Kallistatin depletion also worsened aortic collagen deposition, superoxide formation, and NADPH oxidase activity and elevated inflammatory gene expression, including TNF-α and ICAM-1 (Figures 3(a)–3(d)). Moreover, levels of the antioxidant proteins SIRT1 and eNOS were significantly reduced in the aorta of KS^−/− mice with STZ-induced diabetes (Figure 3(e)), in contrast to the stimulatory effect of kallistatin administration on SIRT1 and eNOS expression [56]. These combined findings indicate that endogenous kallistatin is a protective agent against vascular injury and senescence.

(a)

(b)

(c)

(d)

(e)

Figure 2

Systemic depletion of kallistatin exacerbates aortic senescence. (a) Kallistatin depletion identified by genotyping with the expression of loxp, wild-type (WT) and deletion (del) alleles. (b) Western blot analysis of mouse kallistatin expression in the kidney of WT mice and KS^−/− mice. (c) Representative images and quantitative analysis of β-gal staining of aorta sections from WT, KS^−/− mice with or without STZ treatment. (d, e) PAI-1 and P16^INK4a mRNA levels in mouse aorta. Values are expressed as mean ± SEM. . vs. the WT group, vs. the WT + STZ group.

(a)

(b)

(c)

(d)

(e)

Figure 3

Systemic depletion of kallistatin exacerbates aortic oxidative stress and inflammation. (a) Representative images of superoxide formation in aortas from WT, KS^−/− mice with or without STZ treatment, as indicated by red fluorescence dye DHE. Collagen fibers displayed green autofluorescence in the aorta. (b) NADPH oxidase in mouse aorta. (c) Representative western blot of SIRT1 and eNOS expression in mouse aorta. (d&e) Inflammatory gene expression of TNF-α and ICAM-1 in mouse aorta. Values are expressed as mean ± SEM. . vs. WT group, vs. WT + STZ group.

8. Conclusion

These combined studies reveal a novel role of endogenous kallistatin in protection against vascular injury and senescence. Kallistatin reduces vascular injury and senescence by promoting the migration and function of EPCs. Exogenous kallistatin treatment attenuates aortic injury, senescence, oxidative stress, and inflammation in animal models, while kallistatin deficiency in endothelial-specific or general knockout mice exacerbates vascular injury, senescence, oxidative stress, and inflammation in primarily cultured mouse endothelial cells and diabetic mice. The signaling pathways by which kallistatin inhibits vascular senescence, oxidative stress, and inflammation in EPCs and endothelial cells are shown in Figure 4. Kallistatin is an endogenous protein with no cytotoxic effects. Therefore, kallistatin could potentially be used as an effective therapeutic regimen for aging-associated vascular disease in humans.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This study was supported by the National Institutes of Health grant HL118516.

References

R. Dhingra and R. S. Vasan, “Age as a risk factor,” The Medical Clinics of North America, vol. 96, no. 1, pp. 87–91, 2012.
View at: Publisher Site | Google Scholar
M. Kelly-Hayes, “Influence of age and health behaviors on stroke risk: lessons from longitudinal studies,” Journal of the American Geriatrics Society, vol. 58, Supplement 2, pp. S325–S328, 2010.
View at: Publisher Site | Google Scholar
M. C. White, D. M. Holman, J. E. Boehm, L. A. Peipins, M. Grossman, and S. Jane Henley, “Age and cancer risk: a potentially modifiable relationship,” American Journal of Preventive Medicine, vol. 46, no. 3, pp. S7–15, 2014.
View at: Publisher Site | Google Scholar
J. Wu, S. Xia, B. Kalionis, W. Wan, and T. Sun, “The role of oxidative stress and inflammation in cardiovascular aging,” BioMed Research International, vol. 2014, Article ID 615312, 13 pages, 2014.
View at: Publisher Site | Google Scholar
D. R. Seals, K. L. Jablonski, and A. J. Donato, “Aging and vascular endothelial function in humans,” Clinical Science (London, England), vol. 120, no. 9, pp. 357–375, 2011.
View at: Publisher Site | Google Scholar
J. Case, D. A. Ingram, and L. S. Haneline, “Oxidative stress impairs endothelial progenitor cell function,” Antioxidants & Redox Signaling, vol. 10, no. 11, pp. 1895–1907, 2008.
View at: Publisher Site | Google Scholar
J. D. Erusalimsky, “Vascular endothelial senescence: from mechanisms to pathophysiology,” Journal of Applied Physiology, vol. 106, no. 1, pp. 326–332, 2009.
View at: Publisher Site | Google Scholar
C. Besler, C. Doerries, G. Giannotti, T. F. Lüscher, and U. Landmesser, “Pharmacological approaches to improve endothelial repair mechanisms,” Expert Review of Cardiovascular Therapy, vol. 6, no. 8, pp. 1071–1082, 2008.
View at: Publisher Site | Google Scholar
N. A. Mikirova, J. A. Jackson, R. Hunninghake et al., “Circulating endothelial progenitor cells: a new approach to anti-aging medicine?” Journal of Translational Medicine, vol. 7, no. 1, p. 106, 2009.
View at: Publisher Site | Google Scholar
C. Schmidt-Lucke, L. Rössig, S. Fichtlscherer et al., “Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair,” Circulation, vol. 111, no. 22, pp. 2981–2987, 2005.
View at: Publisher Site | Google Scholar
C. Heiss, S. Keymel, U. Niesler, J. Ziemann, M. Kelm, and C. Kalka, “Impaired progenitor cell activity in age-related endothelial dysfunction,” Journal of the American College of Cardiology, vol. 45, no. 9, pp. 1441–1448, 2005.
View at: Publisher Site | Google Scholar
K. X. Chai, D. C. Ward, J. Chao, and L. Chao, “Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4),” Genomics, vol. 23, no. 2, pp. 370–378, 1994.
View at: Publisher Site | Google Scholar
G. X. Zhou, L. Chao, and J. Chao, “Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence,” The Journal of Biological Chemistry, vol. 267, no. 36, pp. 25873–25880, 1992.
View at: Google Scholar
K. X. Chai, L. M. Chen, J. Chao, and L. Chao, “Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli,” The Journal of Biological Chemistry, vol. 268, no. 32, pp. 24498–24505, 1993.
View at: Google Scholar
J. Chao, K. X. Chai, L. M. Chen et al., “Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats,” The Journal of Biological Chemistry, vol. 265, no. 27, pp. 16394–16401, 1990.
View at: Google Scholar
J. Chao, D. M. Tillman, M. Y. Wang, H. S. Margolius, and L. Chao, “Identification of a new tissue-kallikrein-binding protein,” The Biochemical Journal, vol. 239, no. 2, pp. 325–331, 1986.
View at: Publisher Site | Google Scholar
P. Li, G. Bledsoe, Z. R. Yang, H. Fan, L. Chao, and J. Chao, “Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis,” Immunology, vol. 142, no. 2, pp. 216–226, 2014.
View at: Publisher Site | Google Scholar
B. Shen, M. Hagiwara, Y. Y. Yao, L. Chao, and J. Chao, “Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress,” Hypertension, vol. 51, no. 5, pp. 1358–1365, 2008.
View at: Publisher Site | Google Scholar
J. Chao, H. Yin, Y. Y. Yao, B. Shen, R. S. Smith Jr, and L. Chao, “Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation,” Human Gene Therapy, vol. 17, no. 12, pp. 1201–1213, 2006.
View at: Publisher Site | Google Scholar
J. Chao, J. N. Stallone, Y. M. Liang, L. M. Chen, D. Z. Wang, and L. Chao, “Kallistatin is a potent new vasodilator,” The Journal of Clinical Investigation, vol. 100, no. 1, pp. 11–17, 1997.
View at: Publisher Site | Google Scholar
H. Yin, L. Gao, B. Shen, L. Chao, and J. Chao, “Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-α–induced nuclear factor κB activation,” Hypertension, vol. 56, no. 2, pp. 260–267, 2010.
View at: Publisher Site | Google Scholar
B. Shen, L. Gao, Y. T. Hsu et al., “Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 299, no. 5, pp. H1419–H1427, 2010.
View at: Publisher Site | Google Scholar
L. Gao, P. Li, J. Zhang et al., “Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells,” Journal of the American Heart Association, vol. 3, no. 5, article e001194, 2014.
View at: Publisher Site | Google Scholar
Y. Liu, G. Bledsoe, M. Hagiwara, B. Shen, L. Chao, and J. Chao, “Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling,” American Journal of Physiology. Renal Physiology, vol. 303, no. 8, pp. F1230–F1238, 2012.
View at: Publisher Site | Google Scholar
H. Zhu, J. Chao, A. Raed et al., “Plasma kallistatin is associated with leukocyte telomere length in young African Americans,” The FASEB Journal, vol. 30, 1_Supplement, p. 625.1, 2016.
View at: Google Scholar
T. Minamino, H. Miyauchi, T. Yoshida, K. Tateno, T. Kunieda, and I. Komuro, “Vascular cell senescence and vascular aging,” Journal of Molecular and Cellular Cardiology, vol. 36, no. 2, pp. 175–183, 2004.
View at: Publisher Site | Google Scholar
M. Vasa, K. Breitschopf, A. M. Zeiher, and S. Dimmeler, “Nitric oxide activates telomerase and delays endothelial cell senescence,” Circulation Research, vol. 87, no. 7, pp. 540–542, 2000.
View at: Publisher Site | Google Scholar
J. Chao and L. Chao, “Biochemistry, regulation and potential function of kallistatin,” Biological Chemistry Hoppe-Seyler, vol. 376, no. 12, pp. 705–713, 1995.
View at: Google Scholar
J. Chao, A. Schmaier, L. M. Chen, Z. Yang, and L. Chao, “Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease,” The Journal of Laboratory and Clinical Medicine, vol. 127, no. 6, pp. 612–620, 1996.
View at: Publisher Site | Google Scholar
W. C. Wolf, R. A. Harley, D. Sluce, L. Chao, and J. Chao, “Localization and expression of tissue kallikrein and kallistatin in human blood vessels,” Journal of Histochemistry & Cytochemistry, vol. 47, no. 2, pp. 221–228, 1999.
View at: Publisher Site | Google Scholar
J. Chao, G. Bledsoe, and L. Chao, “Protective role of kallistatin in vascular and organ injury,” Hypertension, vol. 68, no. 3, pp. 533–541, 2016.
View at: Publisher Site | Google Scholar
M. A. De Groote, D. G. Sterling, T. Hraha et al., “Discovery and validation of a six-marker serum protein signature for the diagnosis of active pulmonary tuberculosis,” Journal of Clinical Microbiology, vol. 55, no. 10, pp. 3057–3071, 2017.
View at: Publisher Site | Google Scholar
W. C. Lin, S. L. Lu, C. F. Lin et al., “Plasma kallistatin levels in patients with severe community-acquired pneumonia,” Critical Care, vol. 17, no. 1, p. R27, 2013.
View at: Publisher Site | Google Scholar
J. Chao, P. Li, and L. Chao, “Kallistatin suppresses cancer development by multi-factorial actions,” Critical Reviews in Oncology/Hematology, vol. 113, pp. 71–78, 2017.
View at: Publisher Site | Google Scholar
W. C. Lin, C. W. Chen, L. Chao, J. Chao, and Y. S. Lin, “Plasma kallistatin in critically ill patients with severe sepsis and septic shock,” PLoS One, vol. 12, no. 5, article e0178387, 2017.
View at: Publisher Site | Google Scholar
H. Zhu, J. Chao, I. Kotak et al., “Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents,” Metabolism, vol. 62, no. 5, pp. 642–646, 2013.
View at: Publisher Site | Google Scholar
J. X. Ma, L. P. King, Z. Yang, R. K. Crouch, L. Chao, and J. Chao, “Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy,” Current Eye Research, vol. 15, no. 11, pp. 1117–1123, 1996.
View at: Publisher Site | Google Scholar
H. C. Hatcher, J. X. Ma, J. Chao, L. Chao, and A. Ottlecz, “Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats,” Investigative Ophthalmology & Visual Science, vol. 38, no. 3, pp. 658–664, 1997.
View at: Google Scholar
A. J. Jenkins, J. D. McBride, A. S. Januszewski et al., “Increased serum kallistatin levels in type 1 diabetes patients with vascular complications,” Journal of Angiogenesis Research, vol. 2, no. 1, p. 19, 2010.
View at: Publisher Site | Google Scholar
L. M. Chen, L. Chao, and J. Chao, “Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock,” Life Sciences, vol. 60, no. 17, pp. 1431–1435, 1997.
View at: Publisher Site | Google Scholar
X. Zhi, L. Lin, S. Yang et al., “βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin,” Hepatology, vol. 61, no. 2, pp. 598–612, 2015.
View at: Publisher Site | Google Scholar
J. Chao and L. Chao, “A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats,” Journal of Hypertension, vol. 6, no. 7, pp. 551–558, 1988.
View at: Publisher Site | Google Scholar
J. Chao, Y. Guo, P. Li, and L. Chao, “Opposing effects of oxygen regulation on kallistatin expression: kallistatin as a novel mediator of oxygen-induced HIF-1-eNOS-NO pathway,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 5262958, 8 pages, 2017.
View at: Publisher Site | Google Scholar
A. Stadnicki, U. Mazurek, M. Gonciarz et al., “Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 48, no. 3, pp. 615–623, 2003.
View at: Publisher Site | Google Scholar
C. Urso and G. Caimi, “Oxidative stress and endothelial dysfunction,” Minerva Medica, vol. 102, no. 1, pp. 59–77, 2011.
View at: Google Scholar
J. A. Woods, K. R. Wilund, S. A. Martin, and B. M. Kistler, “Exercise, inflammation and aging,” Aging and Disease, vol. 3, no. 1, pp. 130–140, 2012.
View at: Google Scholar
L. Gao, H. Yin, R. S Smith, L. Chao, and J. Chao, “Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction,” Laboratory Investigation, vol. 88, no. 11, pp. 1157–1166, 2008.
View at: Publisher Site | Google Scholar
P. Li, Y. Guo, G. Bledsoe et al., “Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis,” Critical Care, vol. 19, no. 1, p. 200, 2015.
View at: Publisher Site | Google Scholar
W. H. Yiu, D. W. L. Wong, H. J. Wu et al., “Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress,” Kidney International, vol. 89, no. 2, pp. 386–398, 2016.
View at: Publisher Site | Google Scholar
H. Fujii, K. Ichimori, K. Hoshiai, and H. Nakazawa, “Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process,” The Journal of Biological Chemistry, vol. 272, no. 52, pp. 32773–32778, 1997.
View at: Publisher Site | Google Scholar
B. Shen, R. S. Smith Jr., Y. T. Hsu, L. Chao, and J. Chao, “Kruppel-like factor 4 is a novel mediator of kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression,” The Journal of Biological Chemistry, vol. 284, no. 51, pp. 35471–35478, 2009.
View at: Publisher Site | Google Scholar
M. C. Yoder, “Human endothelial progenitor cells,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 7, article a006692, 2012.
View at: Publisher Site | Google Scholar
T. Imanishi, H. Tsujioka, and T. Akasaka, “Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress,” Current Cardiology Reviews, vol. 4, no. 4, pp. 275–286, 2008.
View at: Publisher Site | Google Scholar
T. Imanishi, T. Hano, and I. Nishio, “Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress,” Journal of Hypertension, vol. 23, no. 1, pp. 97–104, 2005.
View at: Publisher Site | Google Scholar
K. Sugamura and J. F. Keaney Jr, “Reactive oxygen species in cardiovascular disease,” Free Radical Biology and Medicine, vol. 51, no. 5, pp. 978–992, 2011.
View at: Publisher Site | Google Scholar
Y. Guo, P. Li, L. Gao et al., “Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway,” Aging Cell, vol. 16, no. 4, pp. 837–846, 2017.
View at: Publisher Site | Google Scholar
T. Ito, S. Yagi, and M. Yamakuchi, “MicroRNA-34a regulation of endothelial senescence,” Biochemical and Biophysical Research Communications, vol. 398, no. 4, pp. 735–740, 2010.
View at: Publisher Site | Google Scholar
M. Potente and S. Dimmeler, “NO targets SIRT1: a novel signaling network in endothelial senescence,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 9, pp. 1577–1579, 2008.
View at: Publisher Site | Google Scholar
S. Selemidis, G. Dusting, H. Peshavariya, B. Kempharper, and G. Drummond, “Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells,” Cardiovascular Research, vol. 75, no. 2, pp. 349–358, 2007.
View at: Publisher Site | Google Scholar
Y. Guo, L. Chao, and J. Chao, “Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway,” Journal of Cellular and Molecular Medicine, vol. 22, no. 9, pp. 4387–4398, 2018.
View at: Publisher Site | Google Scholar
A. J. Donato, R. G. Morgan, A. E. Walker, and L. A. Lesniewski, “Cellular and molecular biology of aging endothelial cells,” Journal of Molecular and Cellular Cardiology, vol. 89, Part B, pp. 122–135, 2015.
View at: Publisher Site | Google Scholar
C. Rask-Madsen and G. L. King, “Vascular complications of diabetes: mechanisms of injury and protective factors,” Cell Metabolism, vol. 17, no. 1, pp. 20–33, 2013.
View at: Publisher Site | Google Scholar
G. Prévost, H. Bulckaen, C. Gaxatte et al., “Structural modifications in the arterial wall during physiological aging and as a result of diabetes mellitus in a mouse model: are the changes comparable?” Diabetes & Metabolism, vol. 37, no. 2, pp. 106–111, 2011.
View at: Publisher Site | Google Scholar
H. Ota, M. Eto, M. R. Kano et al., “Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 11, pp. 2205–2211, 2010.
View at: Publisher Site | Google Scholar
J. Chao and L. Chao, “Kallistatin in blood pressure regulation transgenic and somatic gene delivery studies,” Trends in Cardiovascular Medicine, vol. 7, no. 8, pp. 307–311, 1997.
View at: Publisher Site | Google Scholar
R. S. Alphonse, A. Vadivel, S. Zhong et al., “The isolation and culture of endothelial colony-forming cells from human and rat lungs,” Nature Protocols, vol. 10, no. 11, pp. 1697–1708, 2015.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2018 Julie Chao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1810

Downloads

1613

Citations